Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Short term Debt (2022)

Denali Therapeutics (DNLI) has disclosed Short term Debt for 1 consecutive years, with $4.4 million as the latest value for Q4 2022.

  • On a quarterly basis, Short term Debt changed N/A to $4.4 million in Q4 2022 year-over-year; TTM through Dec 2022 was $4.4 million, a N/A change, with the full-year FY2022 number at $4.4 million, changed N/A from a year prior.
  • Short term Debt was $4.4 million for Q4 2022 at Denali Therapeutics, up from $1.4 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $4.4 million in Q4 2022 to a low of $1.4 million in Q3 2022.